| Net Loss (Q1 FY27) | ₹24.12 CrQuarterly result |
|---|---|
| Market Cap | ₹17,050 CrMid-cap |
| P/E Ratio (TTM) | 160.5Sector: 46.09 |
| 1-Year Return | -50.74%Price change |
Key highlights
- Ministry of Corporate Affairs approved the appointment via letter dated 8 October 2026
- Mr. Umang Vohra (DIN: 02296740) formally assumes leadership of the Company
- Company reported Q1 FY27 revenue of ₹422.26 crore, a 23.1% year-on-year decline
- Net loss for the June 2026 quarter stood at ₹24.12 crore amid margin compression
- Management maintains a solid liquidity position with consolidated net cash of ₹251.2 crore
Formal Leadership Confirmation for Cohance
Cohance Lifesciences has received final regulatory clearance from the Ministry of Corporate Affairs to formalize the appointment of Mr. Umang Vohra as Chairman and Group CEO. This approval follows the company's initial board notifications issued in April and June 2026.
The leadership confirmation is a critical step for the entity, which was formerly known as Suven Pharmaceuticals Limited, as it stabilizes its management structure following the NCLT-sanctioned amalgamation in March 2025. Vohra is expected to lead the firm through its next phase of commercial expansion and integration of its diversified CDMO and API manufacturing platforms.
Financial Context and Performance Recovery
The executive appointment arrives as the company navigates a challenging financial period, marked by a 31.8% sequential revenue drop in the quarter ended 30 June 2026. Operating margins fell to 0.3% this quarter from 20.4% a year ago, leading to a net loss of ₹24.12 crore. Despite these headwinds, management previously guided that Q1 FY27 represented the year's performance trough.
The company is projecting sequential improvements in the second quarter and a return to year-on-year revenue growth by the second half of the fiscal year, supported by a net cash balance of ₹251.2 crore.
Pipeline and Operational Milestones
- Nine Phase III CDMO assets currently maintained within the platform pipeline
- Four late-stage assets slated for transition to commercial supply in FY27
- Targeting seven new API filings during the current fiscal year to bolster the portfolio
- Successful USFDA cGMP audit at the Jaggaiahpet API facility completed in late 2025
- Implementation of ESOP 2026 plan following stock exchange approvals in July 2026
- Maintenance of active trading window closure pending Q2 FY27 financial results
Regulatory Compliance and Market Positioning
Cohance Lifesciences has maintained a consistent record of regulatory compliance, including securing Department of Pharmaceuticals approval for foreign investment exceeding 74% earlier in 2025. The company’s API manufacturing facilities have recently cleared USFDA inspections with zero observations or Voluntary Action Indicated status, supporting its quality-focused positioning. With the Chairman and Group CEO appointment now fully sanctioned by the Central Government, the company is better positioned to execute its long-term strategy of scaling its commercial-stage assets while managing its expensive valuation metrics relative to the broader pharmaceuticals and biotechnology sector.
| Date | Announcement | Amount |
|---|---|---|
| 23 Jul 2026 | Receipt of stock exchange in-principle approval (BSE and NSE) for Cohance Lifesciences Limited Employee Stock Option Plan 2026 (ESOP 2026)Source: BSE filing | – |
| 12 Sep 2025 | Clearance of USFDA cGMP audit inspection with zero Form 483 observations at API manufacturing facility in Jaggaiahpet, Andhra PradeshSource: expresspharma.in | – |
| 25 May 2025 | Receipt of USFDA Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status for API Unit-IV at Nacharam, HyderabadSource: cohance.com | – |
| 22 Apr 2025 | Regulatory approval from Department of Pharmaceuticals (DoP) under FEMA regulations for foreign investment exceeding 74% post-mergerSource: cohance.com | – |
| 27 Mar 2025 | Approval and sanction from National Company Law Tribunal (NCLT), Mumbai Bench for Scheme of Amalgamation of Cohance Lifesciences Limited with Suven Pharmaceuticals LimitedSource: cohance.com | – |
| 28 Nov 2024 | Approval of Scheme of Amalgamation of Cohance Lifesciences Limited with Suven Pharmaceuticals Limited by equity shareholdersSource: cohance.com | – |
What to watch next
- Announcement of unaudited financial results for Q2 FY27, following the trading window closure on 01 October 2026
- Commercialization of 4 Phase III CDMO assets expected within the FY27 timeframe
- Return to year-on-year revenue growth forecasted for the second half of FY27
- Progress on seven planned new API filings scheduled for completion by March 2027
| Share price | ₹445.65 |
|---|---|
| Market capitalisation | ₹17,050.45 Cr |
| Revenue (annual) | ₹2,268.55 Cr |
| Net profit (annual) | ₹179.23 Cr |
| Revenue (latest quarter) | ₹422.26 Cr-31.80% vs previous quarter |
| Net profit (latest quarter) | -₹24.12 Cr-223.38% vs previous quarter |
| P/E (TTM) | 160.5×Sector 46.09× |
| Promoter holding | 57.49%0.00% QoQ |
| FII holding | 6.5%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Cohance Lifesciences Limited announcing the receipt of Central Government approval for the appointment of Mr. Umang Vohra. Market figures from a third-party data provider.
Track Cohance Lifesciences live
Get the next Cohance Lifesciences filing on Telegram seconds after it lands. 15 days free.
